Liver-specific Bid silencing inhibits APAP-induced cell death in mice

Mareike Maxa1, Ute Schaeper2, Sibylle Dames2

  • 1Institute for Experimental Surgery, Rostock University Medical Center, Schillingallee 69a, 18057, Rostock, Germany.

Insights

Silencing the BH3-interacting domain death agonist (Bid) in mice reduced liver damage and sterile inflammation caused by acetaminophen overdose. However, it did not prevent microcirculatory dysfunction, highlighting Bid

Area of Science:

  • Hepatology
  • Molecular Biology
  • Toxicology

Background:

  • Acetaminophen (APAP)-induced acute liver failure (ALF) is a severe condition with limited treatment options.
  • The precise molecular mechanisms underlying APAP-induced ALF remain incompletely understood.
  • The BH3-interacting domain death agonist (Bid) is investigated as a potential factor in APAP pathology.

Purpose of the Study:

  • To investigate whether silencing Bid expression can prevent APAP-induced ALF in a mouse model.
  • To elucidate the role of Bid in the pathogenesis of APAP-induced liver injury.
  • To assess the therapeutic potential of Bid silencing in APAP-induced liver damage.

Main Methods:

  • Liver-specific siRNA delivery system (DBTC) formulated with siRNA against Bid (siRNABid) was administered to mice 48 hours prior to APAP exposure.
  • Control groups received vehicle (HEPES) or siRNA against luciferase (siRNALuci).
  • Hepatic pathology was evaluated using in vivo fluorescence microscopy, molecular biology techniques, histology, and laboratory analyses.

Main Results:

  • siRNABid significantly reduced Bid mRNA and protein expression in APAP-exposed mice.
  • Bid silencing decreased hepatocellular damage, evidenced by reduced fragmented DNA and necrotic liver tissue.
  • Bid silencing led to a significant reduction in plasma transaminase activities and HMGB1 levels, indicating diminished liver injury and sterile inflammation.

Conclusions:

  • Liver-specific silencing of Bid expression markedly protected against necrotic cell death and subsequent sterile inflammation in APAP-exposed mice.
  • Bid silencing did not protect against APAP-induced microcirculatory dysfunction.
  • The study underscores the importance of Bid in APAP-induced liver injury pathways and suggests Bid silencing as a potential therapeutic strategy.